Cutaneous T-cell lymphomas and their management strategies

被引:1
作者
Pandey, S. S. [1 ]
Garg, S. [2 ]
Dwivedi, A. N. D. [3 ]
Tripathi, R. [4 ]
Tripathi, K. [2 ]
Bansal, M. [1 ]
机构
[1] Banaras Hindu Univ, Inst Med Sci, Dept Dermatol & Venereol, Varanasi 221005, Uttar Pradesh, India
[2] Banaras Hindu Univ, Inst Med Sci, Dept Gen Med, Varanasi 221005, Uttar Pradesh, India
[3] Banaras Hindu Univ, Inst Med Sci, Dept Radiodiag & Imaging, Varanasi 221005, Uttar Pradesh, India
[4] Banaras Hindu Univ, Inst Med Sci, Dept Oral & Maxillofacial Surg, Varanasi 221005, Uttar Pradesh, India
关键词
Cutaneous T-cell lymphomas; management; mycosis fungoides; review; systemic retinoids; EPSTEIN-BARR-VIRUS; WORINGER-KOLOPP-DISEASE; PHASE-II TRIAL; TERM-FOLLOW-UP; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; PROGNOSTIC-FACTORS; CLINICAL CHARACTERISTICS; EUROPEAN-ORGANIZATION; INTERNATIONAL-SOCIETY;
D O I
10.4103/0019-509X.146782
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of lymphoproliferative disorders characterized by the proliferation of skin-homing post-thymic T-cells. It is the second most common extranodal non-Hodgekin's lymphoma. Many variants of mycosis fungoides and CTCLs are known to date, differing in clinical, histological, and immunophenotypic characteristics. Oral involvement has also been reported rarely in CTCLs. Treatment depends on the disease stage or the type of variant. New insights into the disease and the number of emerging novel therapeutic options have made it an interesting area for dermatologists and medical oncologists.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 150 条
[41]  
Felgar RE, 1997, AM J PATHOL, V150, P1893
[42]   Increased CCR4 expression in cutaneous T cell lymphoma [J].
Ferenczi, K ;
Fuhlbrigge, RC ;
Pinkus, JL ;
Pinkus, GS ;
Kupper, TS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (06) :1405-1410
[43]   Primary cutaneous lymphomas:: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients [J].
Fink-Puches, R ;
Zenahlik, P ;
Bäck, B ;
Smolle, J ;
Kerl, H ;
Cerroni, L .
BLOOD, 2002, 99 (03) :800-805
[44]  
Forero A, 2005, J CLIN ONCOL, V23, P6601
[45]  
Foss F M, 2000, Clin Lymphoma, V1 Suppl 1, pS27, DOI 10.3816/CLM.2000.s.005
[46]  
Foss F M, 2000, Clin Lymphoma, V1, P110, DOI 10.3816/CLM.2000.n.009
[47]  
Foss FM, 2000, SEMIN ONCOL, V27, P58
[48]   MOLECULAR MECHANISMS OF HUMAN T-CELL LEUKEMIA/LYMPHOTROPIC VIRUS TYPE-I INFECTION [J].
FRANCHINI, G .
BLOOD, 1995, 86 (10) :3619-3639
[49]   ANGIO-IMMUNOBLASTIC LYMPHADENOPATHY - DIAGNOSIS AND CLINICAL COURSE [J].
FRIZZERA, G ;
MORAN, EM ;
RAPPAPORT, H .
AMERICAN JOURNAL OF MEDICINE, 1975, 59 (06) :803-818
[50]   Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma [J].
Gascoyne, RD ;
Aoun, P ;
Wu, D ;
Chhanabhai, M ;
Skinnider, BF ;
Greiner, TC ;
Morris, SW ;
Connors, JM ;
Vose, JM ;
Viswanatha, DS ;
Coldman, A ;
Weisenburger, DD .
BLOOD, 1999, 93 (11) :3913-3921